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Methicillin-resistant Staphylococcus aureus (MRSA) emerged as a community-associated pathogen (CA-MRSA) in
the past 6 years. This prospective study investigated dermatology outpatients with inflammatory skin diseases, leg
ulcers, and skin infections for Panton-Valentine leukocidin (PVL)-positive S. aureus, often associated with deep skin
infection. In case of PVL positivity, molecular typing and PCR demonstration of resistance genes were performed.
Out of 248 patients, 130 carried S. aureus, 24 being lukS-PV lukF-PV positive. Eighteen were MRSA, 11 of them
belonging to the multilocus sequence typing clonal complex (CC)5, 1 to CC45, and 2/18 to CC8. Out of 18 patients, 4
were CA-MRSA containing lukS-PV lukF-PV as an important trait of CA-MRSA. Out of four CA-MRSA isolates, two
were of type ST080 containing far-1 coding for fusidic acid (FUS) resistance and two were FUS sensitive (ST152 and
ST001). The FUS-sensitive CA-MRSA, which corresponded to the CA-MRSA of ST001 from the United States, was
detected in Germany for the first time, indicating that dermatologists are first in line to detect CA-MRSA. In contrast
to CA-MRSA from other continents, far-1-coded FUS resistance represents a typical marker for the widespread CA-
MRSA ST080 in Europe, especially in Germany. The significant risk factor for the acquisition of CA-MRSA was visits to
foreign countries and/or professional or private contacts with foreigners.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) was first
identified as a nosocomial pathogen (health-care-associated
MRSA (HA-MRSA)). Risk factors for acquisition are diabetes,
hemodialysis, peripheral malperfusion, immunosuppression,
systemic and topical antibiotic treatments during 6 months
before admission, previous surgery, hospitalization, admission
to a nursing home, and contact with MRSA carriers (reviewed
by Lowy, 1998; von Baum et al., 2002). Until 1987 no MRSA
was isolated in a dermatology outpatient clinic (McBride et al.,
1989), whereas a gradual increase in infections with MRSA
from 1.5% of all S. aureus in 1988 to 11.9% in 1996 in the
same dermatology outpatient facilities was observed, and the
prevalence is still increasing (Price et al., 1998). From the early
1990s onward, MRSA infections were reported in otherwise
healthy young individuals, and the respective strains named
‘‘community-associated MRSA (CA-MRSA)’’ (Embil et al.,
1994; Moreno et al., 1995). CA-MRSA is distinct from HA-
MRSA (reviewed by Millar et al., 2007). HA-MRSA corresponds
to definite predominant clonal lineages of the S. aureus
population with some of them having pandemic dissemination
(Oliveira and De Lencastre 2002), whereas CA-MRSA strains
usually represent different lineages. So far, CA-MRSA ST008
(USA 300) is most frequent in the United States but has also
spread to Europe (Witte et al., 2007) and to Asia (Ho et al.,
2007; Zaraket et al., 2007). CA-MRSA ST080 is frequent in
Europe. HA-MRSA is prevalent in health-care settings and
nursing homes affecting immunocompromized patients,
whereas CA-MRSA affects young and healthy individuals in
the community and settings such as combat and ball sports,
military, and prisons. The molecular characteristics of HA-
MRSA differ from those of CA-MRSA in that HA-MRSA
predominantly possesses the type I–IV staphylococcal cassette
chromosome mec (SCCmec), which confers resistance to
currently available b-lactam antibiotics and also many other
non-b-lactam antibiotics, whereas CA-MRSA mainly possesses
SCCmecA type IV or V. HA-MRSA exhibits multidrug resistance
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to drugs such as clindamycin, gentamicin, and fluorochino-
lones (Naimi et al., 2003). CA-MRSA, susceptible to most
groups of antibiotic agents, displays a variable resistance to
fusidic acid (FUS) (often associated with the far-1 gene coding
for a ribosome protection mechanism), oxytetracycline (OTE),
and ciprofloxacin in European isolates (Witte et al., 2004,
2005), and the majority of CA-MRSA has the Panton-Valentine
leukocidin (PVL) gene, which is very rare in HA-MRSA (Millar
et al., 2007). PVL is a bicomponent (lukS-PV and lukF-PV),
pore-forming exotoxin that targets cells of the immune system
such as polymorphonuclear neutrophils. PVL-producing strains
including CA-MRSA have preferentially been isolated from
furuncles, cutaneous abscesses, and severe necrotic skin
infections, suggesting the participation of PVL in the patholo-
gical process (Cribier et al., 1992; Couppie et al., 1994;
Prevost et al., 1995; Miller et al., 2005; Yamasaki et al., 2005).
Although most PVL-related infections are uncomplicated skin
infections, they bear the risk of developing severe systemic
infections such as bacterial endocarditis (Al-Tawfiq and
Aldaabil, 2005; Bahrain et al., 2006). Some are primarily fatal
owing to necrotizing pneumonia (Lina et al., 1999; Gillet
et al., 2002) and necrotizing fasciitis (Miller et al., 2005) for
both adults and children (Fridkin et al., 2005). Owing to the
confusion concerning clear definitions of MRSA detected
outside the hospital setting, there are several limitations of the
current data on CA-MRSA (Salgado et al., 2003).
Therefore, a study on outpatients in the Department of
Dermatology, University of Heidelberg, Germany, was
designed to investigate (1) the frequency of skin-colonizing
or infectious S. aureus, (2) their phenotypic antibiotic
resistance patterns (focusing on the MRSA status and FUS
resistance), (3) whether they contained the PVL gene, and (4)
their molecular characteristics.
RESULTS
Study population and S. aureus positivity
The study was performed from September 2003 to November
2005. A total of 248 patients of the dermatology outpatient
clinic with deep skin infections or superficial erosions and
ulcers due to other underlying skin diseases were enrolled.
Both sexes were nearly equally represented (53% female and
47% male patients). S. aureus was isolated from 130/248
(52.4%) patients. In 54 individuals both sites (anterior nares
as well as lesional skin), in 64 only lesional skin, and in 12
only nares were sampled. In 37 (69%) of the 54 patients, of
whom both sites were sampled, the S. aureus isolates were of
the same phage type. The S. aureus-positive patients (n¼130)
were aged between 1 and 92 years (median: 46 years), and
those individuals with lukS-PV lukF-PV-positive S. aureus
(n¼24) were found to be in nearly the same group of age
(3–90 years, median: 37 years). However, only two patients
were older than 50 years. Approximately one-third of patients
positive for S. aureus (36/130; 27.7%) had deep skin
infections and other S. aureus were collected from superficial
erosions, ulcers, and nares.
Antibiotic resistance. Eighteen out of 130 (13.8%) S. aureus
isolates were MRSA. CA-MRSA are defined as being present
or incubating at the time of admission (within 48 hours after
hospital admission) and were not acquired during health care
during the 12 months prior to actual sampling (Naimi et al.,
2003; Salgado et al., 2003). However, as these definitions
are under discussion and the period of 12 months no longer
holds true for most of the detected CA-MRSA, CA-MRSA in
our study was suspected when sampled in an outpatient
setting or before the actual hospitalization. CA-MRSA was
diagnosed if the following additional criteria were present:
PVL positivity, characteristic multilocus sequence typing
(MLST)/S. aureus protein A (spa) type, and SCCmec type
(IV, V). This was the case for 4/130 (3%) strains (Table 1 and
Figure 1). All four CA-MRSA proved to have a typically
narrow resistance pattern. Both CA-MRSA ST080 isolates
were distinguishable from the other CA-MRSA by far-1-
encoded FUS resistance and mostly showing OTE resistance
as is well known for this genotype (RKI, 2004a). In this
study, OTE resistance is found in 17% of the MRSA strains
(Table 1). In general, 6% of German MRSA strains sent to the
National Reference Centre for Staphylococci (NCS, Werni-
gerode, Germany) are resistant to OTE (NCS, personal
communication). The CA-MRSA ST152 and ST001 only show
resistance to two and three antibiotics, respectively. While
comparing the percentages of resistance phenotypes of
patients with atopic dermatitis with those of other skin
diseases, no apparent differences were found. In 26.2% (34/
130) of patients with a topical FUS treatment history, S.
aureus was detected (Table 2). Four of these 34 isolates were
FUS resistant (11.7 vs 7.3% of the remaining 96 patients
without a FUS history). One of them was a CA-MRSA ST080
containing the FUS resistance-encoding far-1 gene. The three
others (one MRSA ST617, one methicillin-sensitive Staphy-
lococcus aureus (MSSA) ST101, and one MSSA ST121)
were far-1 negative, indicating the existence of alternative
resistance mechanisms. Both groups (with history for FUS
treatment vs no FUS treatment) had one patient positive
for a CA-MRSA with FUS resistance (2.9% of 34 vs 1%
of 96). These data did not reveal a statistically significant
difference between FUS-treated patients and those without
treatment, concerning the prevalence of FUS-resistant
S. aureus in general (P¼0.477) and of CA-MRSA in particular
(P¼0.456).
PVL positivity of the collected S. aureus strains. All isolates
from deep and partly from superficial skin infections were
investigated by PCR for the lukS-PV lukF-PV gene. Twenty-
four S. aureus isolates, including four CA-MRSA isolates,
were lukS-PV lukF-PV positive. They were sampled from
areas of 20 deep skin infections (14 abscesses and 6
furuncles), 2 were collected from superficial infections
(pustules), and 2 strains from colonized lesional skin and/or
nares. They belong to different clonal complexes (CCs)
(Figure 1). Substantial numbers of lukS-PV lukF-PV-positive
S. aureus or CA-MRSA were isolated from patients with deep
skin infections (20/36; 55.6%), whereas only four patients
with superficial wounds including venous leg ulcers (72
tested/94 sampled isolates) had lukS-PV lukF-PV-positive
isolates (5.6%) (Table 3).
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Molecular characteristics of the collected S. aureus strains.
Figure 1 summarizes the molecular characteristics of all PVL-
positive strains and MRSA of our study. The dendrogramm
visualizes clustering of the isolates based on their macro-
restriction profiles in comparison with reference strains.
Cluster analysis reveals the existence of eight distinct clusters.
The dendrogramm on the left side of the figure shows the
capacity of SmaI (Serratia macrorestriction enzyme I) macro-
restriction patterns to discriminate between different clonal
lineages within the two subpopulations of CA-MRSA and HA-
MRSA. This is confirmed by spa typing in connection with
grouping by Based Upon Repeat Pattern algorithm. Typing of
SCCmec revealed that 13/18 MRSA strains were SCCmec
type II, four had SCCmec type IV, and one had SCCmec type
V (Figure 1). Eleven out of 18 belonged to the CC5, including
ST005 and ST225, which is endemic in the region of
Heidelberg, Germany. Two MRSA isolates belonged to
CC8, which is of more international significance. There were
three PVL-negative MRSA isolates (ST005, ST225, and ST617,
the latter belonging to CC45) sampled from deep skin
infections (two abscesses and one furuncle) (Table 1). Of
the four CA-MRSA isolates, three types were found to be
Table 1. MRSA in dermatology outpatients (n=18/130 S. aureus patients; 13.8%)
Strain
Underlying
disease Lesion
Spa
typing
Epidemic
type
lukS–
lukF far-1
FUS
resistance
FUS
therapy PEN OXACIP ERY CLI CMPSXT OTE GENMFL MUP
03-02884 Asthma,
hypertension
Venous
leg ulcer
t008 ST0081  ND No No + + +       + 
04-00194-2 Diabetes,
hypertension
Venous
leg ulcer
t003 ST2251  ND No No + + + + + +    + 
04-00239-1 Peripheral
malperfusion
Venous
leg ulcer
t003 ST2251  ND No No + + + + + +    + 
04-00410 Peripheral
malperfusion,
neoplasm
Venous
leg ulcer
t008 ST0081  ND No No + + + +   +  + + 
04-00411 Diabetes Venous
leg ulcer
t003 ST2251  ND No No + + + + + +    + 
05-01932-2 Resolved
tuberculosis
Venous
leg ulcer
t003 ST2251  ND No No + + + + +     + 
04-00413 Peripheral
malperfusion
Venous
leg ulcer
t1282 ST0051  ND No Yes + + + + +     + 
04-01730 Diabetes,
peripheral
malperfusion
Venous
leg ulcer
t003 ST2251  ND No No + + + + + +    + 
03-02595 Lymphoma,
atopic
dermatitis
Superficial
wound,
cellulitis
t003 ST2251   Yes No + + + + + +    + 
04-00244-1 Atopic
Dermatitis
Superficial
wound
erosion
t003 ST2251  ND No No + + + + + +    + 
03-02594 Hemodialysis,
anemia
Superficial
wound
chronic
erosion
t002 ST005   Yes No + + + i      + 
04-02054 Atopic
dermatitis,
bronchitis
Superficial
wound
pustule
t355 CA-MRSA,
ST152
+ ND No No + + i      +  
03-02773 Acne inversa Abscess t175 CA-MRSA,
ST001
+  No Yes + + i        
05-00941 Diabetes,
neoplasm
Abscess t003 ST225   No No + + + + + +    + 
05-01354 Acne inversa Abscess t305 ST6171   Yes Yes + + + +    + + + 
04-00114-2 Diabetes,
furunculosis
Furuncle t002 ST005  ND No No + + + +      + 
04-00117 Superinfected
insect bite
Furuncle t044 CA-MRSA,
ST0801
+ + Yes No + + i     +  + 
04-00187 Furunculosis Furuncle t044 CA-MRSA,
ST0801
+ + Yes Yes + + i     +   
BURP, Based Upon Repeat Pattern; CA-MRSA, community-associated MRSA; CIP, ciprofloxacin; CLI, clindamycin; CMP, chloramphenicol; ERY,
erythromycin; FUS, fusidic acid; GEN, gentamicin; MFL, moxifloxacin; MRSA, methicillin-resistant Staphylococcus aureus; MUP, mupirocin; ND, not
determined; OTE, oxytetracycline; OXA, oxacillin; PEN, penicillin; SXT, trimethoprim/sulfamethoxazol.
ST, MLST sequence type; +, resistant to antibiotics; i, intermediate resistant.
1As deduced from spa typing in combination with BURP grouping.
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different among each other. Two strains from furuncles (04-
00117 and 04-00187) were identical with regard to their
microbiological and molecular characteristics and belong to
the most frequent CA-MRSA type in Germany (see Figures 1
and 2, lanes 2 and 3).
Risk factor analysis. The risk factor analysis revealed that the
majority of the patients carrying PVL-positive S. aureus (19/
24; 79.2%; P¼0.033) reported visits to foreign countries and/
or professional or private contacts with foreigners, in contrast
to patients with PVL-negative strains (Table 4). However, only
for one strain, the single case of the North American CA-
MRSA (Figure 2), could close contact with foreigners in a
childcare unit be verified. The second major risk factor for the
carriage of PVL-positive S. aureus—although statistically not
significant—was previous antibiotic treatment (17/24; 71%;
P¼0.302) (Table 4). Only a few (7/24; 29%) patients with
PVL-positive strains had been treated with FUS, and 7/24
(29.2%) patients reported hospitalization during the 6 months
before admission. From this study, there is evidence that
patients with atopic dermatitis do not have a statistically
significant increased risk of acquiring PVL-positive S. aureus/
Molecular characterization of MRSA and lukS-PV lukF-PV-positive Staphylococcus aureus from dermatology outpations
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Figure 1. PFGE pattern and phylogenetic tree of MRSA and lukS-PV lukF-PV-positive S. aureus/MRSA of dermatology outpatients with superficial wounds or
deep skin infections via SmaI-macrorestriction patterns expressed as a dendrogramm. The scale indicates the level of pattern similarity. PFGE, pulsed field
gel electrophoresis; SA, lukS-PV lukF-PV-positive S. aureus; MLST, multilocus sequence typing; PVL, Panton-Valentine leukocidin gene (lukS-PV lukF-PV);
SCCmec, staphylococcal cassette chromosome mec; Spa, S. aureus protein A; ND, not determined; AD, atopic dermatitis; Absc., abscess; Sup. skin inf.,
superficial skin infection; BURP, Based Upon Repeat Pattern. *As deduced from spa typing in combination with BURP grouping.
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CA-MRSA (Table 4). In the MRSA group, 13/18 had at least
one well-known risk factor for MRSA colonization: diabetes
mellitus, hemodialysis, venous leg ulcer, atopic dermatitis,
and other chronic erosions. The investigation of the sources
of MRSA in the 18 patients revealed previous hospitalization
in 6 cases, 4 of them with surgery and 5 of them additionally
suffered from diabetes. Two patients were admitted to a
nursing home, one patient had hemodialysis, and two had
atopic dermatitis. Patients with diabetes mellitus (5/16; 31%)
had a nearly threefold increased statistically significant risk
(P¼0.012) of acquiring MRSA when compared to non-
diabetic patients (13/114; 11.4%), none of them had CA-
MRSA. So, in 72% of patients these risk factors can be made
partly responsible for causing colonization with MRSA,
particularly when considering the fact that 11 of these
patients carried an endemic strain of the CC5, including
ST005 and ST225 (Figure 1). In diabetic patients, S. aureus
was sampled in 63% from venous leg ulcers and only in 13%
from deep skin infections. The comparison of colonization
and/or infection with MRSA including CA-MRSA of patients
with atopic dermatitis and of those with other skin diseases
revealed a similar percentage of carriage in both groups:
10.7% (3/28 of atopic dermatitis patients) vs 14.7% (15/102)
remaining patients with other skin diseases. Concerning
antibiotic treatment, 19/34 (56%) patients with a history of
previous FUS treatment and who were positive for S. aureus
had additionally received antibiotics during the 6 months
before sampling. Eleven out of 34 had a positive history for
deep skin infection. In 13 patients (4 with venous leg ulcers
and 9 with atopic dermatitis), the collected strains were
colonizing lesional skin.
DISCUSSION
Although the significance of MRSA in dermatology is
obvious, the prevalence of multiresistant strains in skin
lesions and their molecular characteristics have not been
investigated thoroughly. Despite the worldwide increase in
prevalence of MRSA, very few studies on surveillance of
MRSA of dermatology outpatients exist. Preliminary investi-
gations on MRSA in dermatology outpatients, shown to be
HA-MRSA consisting of MLST CC5 (formerly named ‘‘Rhi-
ne–Hesse’’ epidemic strain) or local epidemic strains,
revealed that chronic ulcers and erosions represented
significant additional risk factors, pointing to a considerable
impact of dermatological diseases in this particular context
(Jappe et al., 2004). The first prospective study on the
prevalence of CA-MRSA in dermatology was performed in
France nearly in parallel to the project presented here,
exclusively investigating S. aureus strains sampled from 207
primary and secondary skin infections in 197 patients
for their MRSA status, strictly following the definition of
CA-MRSA and HA-MRSA, provided by Salgado et al. (2003)
(Del Giudice et al., 2006). Our study, in contrast, investigated
not only primary and secondary skin infections in 248
outpatients but also skin colonization. In addition, we
focused on PVL-positive strains without MRSA status and
risk factors associated with HA-MRSA and CA-MRSA.
One hundred and thirty patients carried S. aureus,
approximately one-third suffering from deep skin infections.
Eighteen strains were MRSA, 11 endemic strains with a broad
phenotypic resistance pattern, and 4 strains proved to be CA-
MRSA. The CA-MRSA-detection rate of 3% was comparable
to that in the French study. In contrast to the French study
(Del Giudice et al., 2006), where the CA-MRSA had similar
pulsed field gel electrophoresis types comparable to the
French CA-MRSA reference strain, we detected different
Table 2. Occurrence of FUS-resistant S. aureus and CA-MRSA in dermatology outpatients
No. of patients with
S. aureus
FUS-resistant S. aureus (including
MRSA and CA-MRSA) CA-MRSA
FUS-resistant
CA-MRSA
Patients with S. aureus (total number) 130 11 (8.5 %) 4 (3.0 %) 2 (1.5 %)
Patients with FUS treatment 34 4 (11.7 %)1 2 (5.8 %) 1 (2.9 %)2
Patients without FUS treatment 96 7 (7.3 %)1 2 (2.0 %) 1 (1.0 %)2
CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus; FUS, fusidic acid.
1Difference statistically nonsignificant (Fisher’s exact test: P=0.477).
2Difference statistically nonsignificant (Fisher’s exact test: P=0.456).
Table 3. Clinical origin of S. aureus isolates (skin
infection and skin colonization*) and their capacity of
PVL production (n=108)
lukS-PV lukF-PV
Positive (n=24) Negative (n=84)
Clinical origin
MRSA
(n=4)
MSSA
(n=20)
MRSA
(n=14)
MSSA
(n=70)
Abscesses (25) 1 13 2 9
Furuncles (11) 2 4 1 4
Impetigo (4) 0 0 0 4
Superficial skin infections
(27)
1 1 3 22
Atopic dermatitis* (13) 0 1 0 12
Venous leg ulcer* (28) 0 1 8 19
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-
sensitive Staphylococcus aureus; PVL, Panton-Valentine leukocidin.
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CA-MRSA strains. One originating from North America
(ST001) has been detected in Germany for the first time
(Witte et al., 2005). It is the second most prevalent CA-MRSA
in the United States. CA-MRSA ST152 isolated from a patient
with atopic dermatitis is widely spread in the southeast of
Europe (Mueller-Premru et al., 2005). The PVL-negative
MRSA strain ST225 was dominant in our study and has
increasing significance in central Europe (RKI, 2007). MRSA
ST005 is endemic in the region from which our patients were
collected (Rhine–Hesse strain). ST008 is a well-established
strain in health-care settings.
Twenty of 36 patients with deep skin infections had PVL-
positive strains (55.6% (55% of furuncles and 56% of
abscesses)). There were even MRSA sampled from two
abscesses and one furuncle, lacking characteristic CA-MRSA
traits. Similarly designed studies had revealed results on PVL-
positive strains from deep skin infections with rates between
35.2 and 70.8% (Nolte et al., 2005; Yamasaki et al., 2005).
From our as well as the above mentioned data, it is obvious
that not everyone with invasive S. aureus infections carries
PVL-positive (methicillin-resistant) strains, which contradicts
the significance of PVL positivity as a conditio sine qua non
(Couppie et al., 1994; Lina et al., 1999) for the development
of deep skin infection. Our findings are additionally
supported by recent investigations on the pathogenic
mechanism of PVL providing evidence that PVL is not the
major virulence determinant of CA-MRSA (Said-Salim et al.,
2005; Voyich et al., 2006; Labandeira-Rey et al., 2007;
Bubeck Wardenburg et al., 2007). Although there are
contradicting findings on the role of PVL in the pathogenesis
M
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Lane Strain Lesion Risk factors Antibiotic
treatment 
Occurrence
1 03-02773 Abscess
(acne inversa)
Professional contact
(kindergarten) to a US
 American child who
 had recently  immigrated
FUS, other
 antibiotics,
steroids
Endemic in
North America 
2 04-00117 Furuncle Native African,
 immigration to Germany
 3 months prior to visit;
clinic symptoms
 since immigration 
Antibiotics Germany, France,
Scotland, Norway,
 Switzerland
3 04-00187 Furuncle Journey to Turkey
5 months prior to
 first symptoms;
 two children
 with furunculosis;
one child known
 MRSA carrier
FUS, other
 antibiotics,
steroids
Germany, France,
 Scotland, Norway,
 Switzerland
4 04-02054 Pustule
(atopic dermatitis)
Native Yugoslavian; last
 visit there 12
 months prior to
 admission; 
chronic bronchitis 
Topical
antibiotics
Slovenia
(Mueller-Premru
 et al., 2005),
 Switzerland
Figure 2. Clinical characteristics of CA-MRSA isolates detected in this prospective study on S. aureus from dermatology outpatients with colonized
superficial wounds or deep skin infections.
Table 4. Analysis of risk factors for S. aureus/MRSA
acquisition in patients (n=108) with MRSA compared
with patients with MSSA
Patients with
MRSA (n=18)
Patients with
MSSA (n=90)
Associated factors during the
previous 6 months
PVL+
(n=4)
PVL
(n=14)
PVL+
(n=20)
PVL
(n=70)
Visits to foreign countries/contact to
foreigners
4 4 15 24
Hospitalization 0 6 7 15
Topical FUS 2 2 5 18
Antibiotics 4 11 13 45
Atopic dermatitis 1 2 2 18
Glucocorticosteroids 2 2 5 25
Diabetes mellitus 0 5 0 8
FUS, fusidic acid; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-sensitive Staphylococcus aureus; PVL, Panton-Valen-
tine leukocidin.
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of invasive S. aureus infections and although high expression
of small cationic peptides with the capacity for recruitment
and destruction of neutrophilic granulocytes seems to be more
important (Wang et al., 2007), there is a strong epidemiolo-
gical association of the PVL genes with CA-MRSA (Lina et al.,
1999), suggesting PVL to be a highly informative epidemio-
logical marker. The genetic determinants of lukS-PV lukF-PV
are associated with particular lines of S. aureus, which have
an unequivocal relation to particular isolates associated with
deep skin infections: MLST type 121 and ST030 (see Figure 1),
the former being dominant in this study. S. aureus ST121
caused an outbreak of furunculosis in a village in Germany
(Wiese-Posselt et al., 2007). Strains belonging to the CC
ST030 had been isolated from furunculosis patients in the
early 1940s after World War II. The same group was also
associated with mastitis puerperalis and severe newborn
infections during the 1950s known then as phage type 80/81
(Robinson et al., 2005). However, nowadays these strains can
be found in patients with furunculosis and tropical pyomyo-
sitis (Cuny et al., 1996). All together, the PVL-positive
S. aureus strains of our study collected from deep skin infections
have a narrow resistance pattern and do not show the
selection of particular antibiotic resistance profiles, which
may be due to the lack of selective pressure, because
abscesses and furuncles are treated surgically and afterward
antiseptically rather than with systemic antibiotic therapy in
the dermatology department of the University of Heidelberg,
Heidelberg, Germany.
HA-MRSA and CA-MRSA carriers were investigated for
risk factors. A significant factor for the acquisition of CA-
MRSA was visits to foreign countries and/or professional or
private contacts with foreigners, which is in accordance with
previous reports (Maier et al., 2005; Helgason et al., 2008). It
also proved to be a major risk factor for the acquisition of
PVL-positive S. aureus strains in general, together with
previous antibiotic treatment. The majority (72%) of MRSA-
carrying patients in the presented study had well-known risk
factors for HA-MRSA acquisition. The risk of patients with
diabetes mellitus to acquire HA-MRSA is statistically sig-
nificant and increased by nearly threefold when compared to
non-diabetic patients, possibly having acquired these strains
in regular ‘‘ambulatory care.’’ Interestingly, diabetic patients
had no PVL-positive S. aureus. They were mostly elderly
patients, whereas PVL-positive strains mainly were sampled
from much younger individuals and are only rarely found in
hospital settings, which is in accordance with the literature.
From our data, there is no evidence that patients with atopic
dermatitis are prone to be infected by MRSA, neither CA-
MRSA nor HA-MRSA.
The frequency for FUS resistance detected in our study is
8.5% (S. aureus, including MRSA, of 11/130 dermatology
outpatients) and, therefore, twice as high as the frequency of
3–4% of all MRSA sent to the NCS from all hospital
disciplines (RKI, 2004b) of the last 8–10 years. FUS resistance
was found in one lukS-PV lukF-PV-positive MSSA of the
clonal group ST30 without far-1 positivity, indicating that
FUS resistance had developed independently of the far-1
gene, probably due to a mutation or other unknown
resistance mechanisms. Data on FUS resistance of S. aureus
in dermatology generally are controversial. The community
isolates are composed of a heterogeneous mixture of strains.
According to Turnidge and Collignon (1999), the selection of
FUS-resistant strains does not occur at high frequency in
clinical practice, an observation supported by investigations
in children with impetigo, not even after long-term treatment
(Koning et al., 2002). This is, however, in contrast to a Dutch
group that observed an increase of FUS resistance in S. aureus
strains isolated from atopic dermatitis in-patients from 9.7 to
23.4% between 1995 and 2001 (Peeters et al., 2002).
Ravenscroft et al. (2003) and Shah and Mohanraj (2003)
described even higher rates of FUS resistance in patients with
atopic dermatitis, which may be due to the adhesion of
S. aureus to the skin of patients with this particular condition.
Our results do not show significant differences between
patients with and without topical FUS treatment concerning
the emergence of FUS-resistant S. aureus in general and CA-
MRSA in particular. However, such a development cannot
completely be excluded considering the relatively low
number of treated patients in our study, which is due to the
fact that in the Heidelberg dermatology department a policy
on a most restricted use of topical antibiotics has been
followed for years. Furthermore, our data are the result of a
one-point analysis at the day of admission rather than a time
course investigation. To strengthen our observation, future
analysis of the isolates before and after FUS treatment should
be performed with regard to FUS susceptibility.
Previous studies as well as our results demonstrate that
dermatologists are first in line to detect the spread of virulent
resistant S. aureus strains, thereby surveying the changes
occurring in S. aureus epidemiology, relevant for antibiotic
resistance policies as well as clinical symptoms. The primary
transmission route of PVL-positive S. aureus/CA-MRSA is
skin-to-skin contact with no skin effraction and indirect
contact of contaminated objects in close communities (for
example, family, sports, daily childcare, and health-care
facilities) (Osterlund et al., 2002; Linde et al., 2005; Lu and
Holtom, 2005; Mueller-Premru et al., 2005). Clinicians
should be aware of the major high-risk groups for CA-MRSA.
Outbreaks of any pyoderma, soft tissue abscesses, and
recurrent skin infections justify the investigation for PVL-
positive S. aureus/CA-MRSA (Fleming et al., 2006), especially
with the patient’s history containing information as men-
tioned above. Although there is no definite proof for PVL
being the ultimate cause of deep skin infections, it seems to
be a highly informative epidemiological marker for severe
infections and, in some cases, CA-MRSA. Suspected infection
and/or colonization with CA-MRSA needs particular hygiene
procedures, as the affected individuals and settings as well as
the vehicles differ from those of HA-MRSA-associated
circumstances. Treatment of CA-MRSA-related abscesses
and furuncles includes early and adequate incision and
drainage; antibiotic therapy is of secondary importance if
cellulitis or bacteremia is not a concern. Together with the
previous two prospective studies (Maier et al., 2005; Del
Giudice et al., 2006), our data provide evidence for the
necessity to adopt the existing guidelines for management of
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MRSA carriers in hospitals, nursing homes, and outpatient
clinics. Obtaining a culture and resistance profile of all skin
diseases holding the risk of PVL-positive S. aureus and CA-
MRSA colonization should be encouraged to become
routine. Our results demonstrate the occurrence of CA-MRSA
in dermatology outpatients also in Germany. With increasing
prevalence of CA-MRSA as expected, the empiric use of
b-lactam antimicrobials such as cephalosporins or penicillins
without wound culturing is hazardous.
MATERIALS AND METHODS
The study was performed in the dermatology outpatient clinic of the
Department of Dermatology and Venerology, University of Heidel-
berg, Heidelberg, Germany. The outpatient clinic is attended by
100–120 patients a day.
Study population and sampling
A study population of 248 dermatology outpatients with venous
leg ulcers, wounds, erosions accompanying inflammatory skin
diseases, deep skin infections (abscesses and furuncles) as well as
superficial skin infections such as impetigo, superficial wound
infections, or pyoderma participated in the study. Swabs were taken
from lesional skin and in nearly 50% of the patients additionally
from anterior nares using a commercially available transportation
medium (Trans-swab, Mast, Rheinfeld, Germany). The fact that not
in any case nasal swabs were taken is due to the logistic fact that
swabs were taken by medical personnel not always acquainted with
the study protocol (for example, in the surgery). The data on
potential risk factors for MRSA acquisition were abstracted from the
medical history and recorded by a standardized questionnaire. If a
patient was sampled more than once, the patient was counted
only once.
Bacterial strains
All isolates were from primary skin and soft tissue infections and
from colonized lesions of patients with erosive inflammatory skin
diseases and venous leg ulcer—sometimes additionally from the
nares. A set of representative reference strains was included in the
study (Figure 1).
All swabs were cultured on blood agar plates containing 8mg l1
polymyxin to suppress the growth of Gram-negative bacteria. S.
aureus was identified based on colony morphology and using
plasma coagulation.
Antimicrobial susceptibility testing
All available isolates were tested for susceptibility to the following
antibiotics: penicillin, oxacillin, moxifloxacin, erythromycin,
clindamycin, OTE, gentamicin, chloramphenicol, rifampicin, fosfo-
mycin, vancomycin, teicoplanin, linezolid, trimethoprim/sulfa-
methoxazole, ciprofloxacin, quinupristin/dalfopristin, FUS, and
mupirocin. Mupirocin had been included because it is widely used
for MRSA eradication in the nares. Susceptibility testing was
performed by broth microdilution according to DIN 58940
(Deutsches Institut fu¨r Normung, 2004) using S. aureus strains NCTC
6571, SA403, SA159, and 1309/80 as reference strains for internal
quality assurance. For oxacillin resistance detection, an additional
special tube test was performed (about 107 colony-forming units
were inoculated into 1ml ISO Sensitest broth containing 2% NaCl
and 2 mgml1 oxacillin and 8mgml1 sulbactam) (Cuny et al., 1999).
Oxacillin-resistant isolates were screened for themecA gene by PCR.
Criteria for infections were as defined by Centers for Disease Control
(CDC) guidelines (Garner et al., 1988). Isolates not associated with
infections were classified as colonizing.
Strain typing
Initially, all isolates were typed by phage typing for a first grouping
(Witte et al., 1988). All S. aureus obtained from deep skin infections
(abscesses and furuncles) and all lukS-PV lukF-PV-positive isolates,
as well as S. aureus phage group II known as particular line for
causing deep skin infections, and isolates with oxacillin and FUS
resistance were characterized by SmaI macrorestriction analysis,
according to the standardized HARMONY protocol (Murchan et al.,
2003). Resulting band patterns were analyzed using BioNumerics
(Applied Maths, Sint Martens-Latem, Belgium). Similarity values
were computed using the Dice coefficient. Clustering was performed
based on unweighted pair group arithmetic averaging. Additionally,
the polymorphic X-region of spa gene—coding for a surface
compound of S. aureus—was investigated. The X-region of the
protein A gene consists of direct repeats exhibiting an extensive
polymorphism. The number of repeats and repeat succession define
the spa type. Sequence data were analyzed according to Harmsen
et al. (2003) using the software Ridom StaphType (Ridom GmbH,
Wu¨rzburg, Germany; see http://www.spaserver.de). Spa typing in
connection with the new clustering algorithm Based Upon Repeat
Pattern integrated into the software for grouping related spa types
together allows classification of bacterial strains with a wide
congruence to SmaI macrorestriction analysis (pulsed field gel
electrophoresis)—the current ‘‘gold standard’’ (Strommenger et al.,
2006b). Selected isolates, which were grouped ambiguously by SmaI
macrorestriction and spa typing, were investigated via MLST,
allowing an assignment to clonal lineages. The MLST primers and
PCR conditions were chosen as described by Enright et al. (2002).
Sequencing reactions were carried out using the ABI PRISM BigDye
Terminator cycle sequencing ready reaction kit (Applied Biosystems,
Foster City, CA). Allele types and resulting sequence types were
assigned at the S. aureus MLST database (http://www.mlst.net).
Characterization of strains by PCR
For all MRSA strains, staphylococcal genomic DNA was extracted
from 2ml overnight culture with the DNeasy Tissue kit (Qiagen,
Hilden, Germany) by using lysostaphin (100mg l1; Sigma, Tauf-
kirchen, Germany) to achieve bacterial lysis.
ThemecA gene, which codes for the additional penicillin binding
protein PBP2a mediating methicillin resistance, was detected as
described previously (Witte et al., 1994). All S. aureus isolates,
obtained from deep skin infections and partly from superficial
wounds, and all FUS-resistant S. aureus were investigated for the
genetic determinants for PVL production and FUS resistance,
lukS-PV lukF-PV and far-1, respectively. The presence of the
corresponding genes was investigated by PCR as described
previously (Witte et al., 2005). Typing of SCCmec was performed
as described previously (Strommenger et al., 2006a).
As the specimens and information on potential risk factors
were sampled for infection control following the infection control
guideline of the university hospital, which is based on the
recommendations of the NCS (Robert-Koch-Institute, Germany)
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and the Protection against Infection Act (Infektionsschutzgesetz);
formal ethical approval was not required (Ethics Committee,
University of Heidelberg, Germany).
Statistics
A univariate comparison of data was performed using Fisher’s exact
test for categorical data (SPSS for Windows; SPSS Inc., Chicago, IL),
and P-values o0.05 were considered significant.
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